TRACON Pharmaceuticals (TCON) 10-K2017 FY Annual report

Filed: 1 Mar 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abiraterone, acuity, adhesion, AFP, Amrbx, angiography, Aspire, ATM, Bascom, BCVA, bioactivity, biochemical, brolucizumab, bulk, Bulletin, CDE, CFDA, checkpoint, chemoradiation, CI, coherence, CST, error, Exudation, fetoprotein, flat, fluorescein, futility, HCC, heightened, hosted, hybrid, IASLC, intravitreal, IRC, levatinib, loosen, Macau, mandate, mandated, Miami, monotherapy, mTOR, myeloid, offshore, Oncotarget, OS, paired, Palmer, parallel, passed, passing, payoff, PCAOB, placebo, proportion, rapamycin, Regeneration, repatriated, scrutiny, SHARP, sixteen, source, spectral, spontaneously, subfield, suppressor, syngeneic, Taiwan, territory, ticker, tomography, Torisel, TRAXAR, urge, withdrew, yellowish, Yokohama, Zytiga

Removed: academic, acid, activating, adult, alleviate, antihyperlipidemic, antitumor, beta, bevacizumab, Biogen, Bitar, BMP, bone, broadening, buildup, cardiac, Casey, Celgene, chart, choriocarcinoma, Circulation, cloned, collagen, compensatory, conceptually, conjunction, continuously, contributor, copy, dark, darkly, deficient, demonstrating, denoted, deposition, detected, deterioration, disability, dual, durability, endothelium, Eng, Esbriet, escalating, escalation, excessive, fat, Fibrogen, Fifty, fourth, freestanding, function, Galmed, gemfibrozil, Genfit, Genitourinary, Gilead, heart, Hematology, histologic, hypertension, idec, idiopathic, Immuron, importance, inflammation, insulin, Intercept, InterMune, IPF, knowable, Lane, Lastly, Logan, lowering, malignant, mediate, metformin, mice, Mochida, morphogenic, NASH, NasVax, Nineteen, nintedanib, nonalcoholic, OFEV, Patricia, PDGF, pentoxifylline, percent, permanent, pirfenidone, plasma, platelet, platinum, play, plc, preserved, profiled, proteinuria, proven, PSA, pulmonary, radiation, randomize, rarely, reclassified, recognizing, remeasurement, reproductive, rest, reversed, salary, Sanofi, saturate, scleroderma, secretion, Shire, showed, signal, Squibb, stain, stained, star, suggesting, syndrome, Takeda, topline, triangle, underwent, unvested, Ursodeoxycholic, ursodiol, ventricle, ventricular, week, WT, Xeloda

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated TCON transcripts

TCON similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Charles P. Theuer, M.D., PhD., President and Chief Executive Officer of TRACON Pharmaceuticals, Inc. (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)this Annual Report on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.


Date: February 28, 2018	/s/ Charles P. Theuer, M.D., Ph.D.
	Charles P. Theuer, M.D., Ph.D
	President and Chief Executive Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.